Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23304301 | 0.85 | GBA1 (0.49) | ALDH1A1 | |
| SCHEMBL23684245 | 0.84 | HTR2A (0.46) | KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL23304363 | 0.84 | HRH3 (0.41) | HRH3KDM4EALDH1A1PKM | |
| SCHEMBL23684051 | 0.82 | CKS1B (0.48) | KMT2AMEN1 | |
| SCHEMBL23304587 | 0.81 | HRH4 (0.41) | HRH4HRH3KMT2AKDM4EALDH1A1 | |
| SCHEMBL23304591 | 0.79 | CKS1B (0.48) | KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL20951481 | 0.74 | PIK3CA (0.68) | HRH4CHEK1 | |
| SCHEMBL1579769 | 0.73 | KDM4E (0.45) | HRH3KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL22549339 | 0.73 | HRH4 (0.59) | HRH4AURKA | |
| Hydrochloric Acid SCHEMBL20951268 | 0.73 | PIK3CA (0.67) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | HRH4 91/4885CHEK1 4561/4885HRH3 183/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | HRH4 91/4885CHEK1 4561/4885HRH3 183/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | HRH4 91/4885CHEK1 4561/4885HRH3 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.